Aclaris Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aclaris Therapeutics Inc 's ROA in the second quarter of 2026?
Aclaris Therapeutics Inc recorded a cumulative net loss of $-76 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -29.93%.

However, within the Healthcare sector 506 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3767, from total ROA ranking in the first quarter of 2026 at 4378.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	150.52 %	-0.61 %	-27.48 %	-3.54 %	16.87 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-76	-70	-65	-142	-135
Return On Assets (TTM)	-29.93 %	-38.38 %	-35.71 %	-71.91 %	-67.79 %
ACRS's Total Ranking	# 3767	# 4378	# 4219	# 4257	# 4337
Total Assets (TTM) in million	476	199	160	177	190
Seq. Total Assets Change	139.72 %	23.84 %	-9.19 %	-7.08 %	-4.9 %
Seq. Net Income Change	-	-	-	-	-

ACRS's 5 Years Annual ROA >> Back to ACRS Management Effectiveness >> Compare ACRS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 204
Sector	# 507
Overall	# 3785

Return On Assets Statistics
High	Average	Low
78.57 %	-44.94 %	-97.34 %
(Mar 31 2016)		(Mar 31 2020)

News about Aclaris Therapeutics Inc Return on Assets ROA

Aclaris Therapeutics: Charting a Path to Financial Reinvention and Leadership Reinforcement

Aclaris Therapeutics, a prominent player in the healthcare sector, has recently announced significant leadership changes and a strategic business review. The decision comes after a period of financial underperformance, with the company s year-to-date stock performance showing a decline of 12%. Additionally, Aclaris Therapeutics reported a net loss of $115 million for the twelve months leading up to the third quarter of 2023, resulting in a negative return on assets (ROA) of -48.43%. This article delves into the implications of these developments and the potential impact on the company s overall market standing within the healthcare sector.
Transition in Leadership:
One of the significant changes within Aclaris Therapeutics is the stepping down of Douglas Manion, M.D., as the Chief Executive Officer, President, and Member of the Board of Directors. Dr. Manion had been at the helm of the company during a period of financial struggles. This leadership transition presents an opportunity for the company to explore fresh perspectives and operational strategies. Aclaris Therapeutics will be on the lookout for a new CEO who can steer the company towards stability and profitability.

Financial Statements
Aclaris Therapeutics Inc 's Assets	$ 476 million	ACRS's Balance sheet
Aclaris Therapeutics Inc 's Income	$ -22 million	Quarterly ACRS's Income Statement
ACRS's Income by Division		See ACRS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-0.09 %	10.9 %	-22.02 %	1.85 %	254.9 %
Total Assets in million	221	221	200	256	251
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-65	-132	-88	-87	-91
Annual Return On Assets	-29.37 %	-59.69 %	-44.35 %	-33.97 %	-36.17 %

ACRS's 5 Years Annual ROA >> Back to ACRS Management Effectiveness >> Compare ACRS ROA to its Competitors

More Return On Assets Ratios
ACRS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACRS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACRS's Competitors
Subscribers only: Roa for Aclaris Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ACRS's Customers

You may also want to know
ACRS's Roi	ACRS's Inventory Turnover Ratio	ACRS's Growth Rates	ACRS's Dividend Comparisons
	ACRS's Profitability Ratios	ACRS's Asset Turnover Ratio	ACRS's Dividend Growth
ACRS's Roe	ACRS's Valuation Ratios	ACRS's Financial Strength Ratios	ACRS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:27:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.